2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib.
BeiGene today announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinaemia.